A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

Recruiting

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

Sponsor:

Skyline Therapeutics

Code:

NCT06346600

Conditions

Neovascular (Wet) Age-related Macular Degeneration

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

SKG0106

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Skyline Therapeutics on 2024-04-04.